Real world comparision of baricitinib (n 138) and tofacitinib (n 156) in #RA patients shows at wk 24, BARI out performed TOFA - CDAI remission (40.4 vs 28.3%) and CDAI LDA (81.6 vs 69.3%); safety signals were equal between groups. https://t.co/0quNNGB18K